

UNDER THE SPOTLIGHT

A FAMILY STORY:

Navigating key inhibitor management challenges in haemophilia A

Wednesday, 2 February 2022
18:00–19:00 CET



JOIN US AT EAHAD VIRTUAL CONGRESS 2022

Join us on Wednesday, 2 February 2022
18:00–19:00 CET

AGENDA



Welcome and introduction

Chair: William Beau Mitchell, New York, US



Making informed treatment decisions in your PUPs

Maria-Elisa Mancuso, Milan, Italy



Factoring out inhibitors: Immune tolerance induction with simoctocog alfa

Georgina Hall, Oxford, UK



Exploring the future of inhibitor management

Robert F Sidonio Jr, Atlanta, US



Q&A, concluding remarks

Chair and all speakers

This symposium is for healthcare professionals only and is organised and sponsored by Octapharma. Prescribing information may vary depending on local approval in each country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the summary of product characteristics. Product information is available online at <https://www.octapharma.com/products/product-overview/nuwiq/>. Products will be discussed.

Simoctocog alfa is approved for use in the treatment and prophylaxis of bleeding across all age groups of patients with haemophilia A (congenital factor VIII deficiency) in the EU, US, Canada, Australia, Latin America and Russia.